Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jul 13

PMID 39001400

Authors

Ji Hyun Kim

Eun Taeg Kim

Se Ik Kim

Eun Young Park

Min Young Park

Sang-Yoon Park

Myong Cheol Lim

Affiliations

Soon will be listed here.

Abstract

Background: This multicenter retrospective study aimed to investigate the prognostic value of the CA-125 elimination rate constant K (KELIM) in EOC patients who received platinum-based chemotherapy followed by PARP inhibitors, in either upfront or interval treatment settings.

Methods: Between July 2019 and November 2022, we identified stage III-IV EOC patients who underwent primary or interval cytoreductive surgery and received olaparib or niraparib. Individual KELIM values were assessed based on validated kinetics and classified into favorable and unfavorable cohorts.

Results: In a study of 252 patients undergoing frontline maintenance therapy with olaparib or niraparib, favorable KELIM (≥1) scores were associated with a higher PFS benefit in the primary cytoreductive surgery (PCS) cohort (hazard ratio (HR) for disease progression or death 3.51, 95% confidence interval (CI); 1.37-8.97, = 0.009). Additionally, within the interval cytoreductive surgery (ICS) cohort, a favorable KELIM score (≥1) significantly increased the likelihood of achieving complete resection following cytoreductive surgery, with 59.4% in the favorable KELIM group compared to 37.8% in those with unfavorable KELIM.

Conclusions: A favorable KELIM score was associated with improved PFS in patients with advanced EOC undergoing PCS. Furthermore, in the ICS cohort, a favorable KELIM score increased the probability of complete cytoreduction.

References

Wang Y, Bernhardy A, Cruz C, Krais J, Nacson J, Nicolas E . The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016; 76(9):2778-90. PMC: 4874568. DOI: 10.1158/0008-5472.CAN-16-0186. View

You B, Sehgal V, Hosmane B, Huang X, Ansell P, Dinh M . CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2022; 41(1):107-116. PMC: 9788978. DOI: 10.1200/JCO.22.00430. View

Kristeleit R, Drew Y, Oza A, Domchek S, Banerjee S, Glasspool R . Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. Br J Cancer. 2022; 128(2):255-265. PMC: 9902459. DOI: 10.1038/s41416-022-02022-y. View

Swisher E, Kwan T, Oza A, Tinker A, Ray-Coquard I, Oaknin A . Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021; 12(1):2487. PMC: 8093258. DOI: 10.1038/s41467-021-22582-6. View

Colomban O, Tod M, Peron J, Perren T, Leary A, Cook A . Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectr. 2020; 4(3):pkaa026. PMC: 7306189. DOI: 10.1093/jncics/pkaa026. View

Corbaux P, You B, Glasspool R, Yanaihara N, Tinker A, Lindemann K . Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. Eur J Cancer. 2023; 191:112966. DOI: 10.1016/j.ejca.2023.112966. View

Intidhar Labidi-Galy S, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T . Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecol Oncol. 2019; 155(2):262-269. DOI: 10.1016/j.ygyno.2019.09.008. View

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Fong P, Yap T, Boss D, Carden C, Mergui-Roelvink M, Gourley C . Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010; 28(15):2512-9. DOI: 10.1200/JCO.2009.26.9589. View

10.

Kim J, Cho H, Park E, Han K, Kim E, Lee J . Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2023; 33(12):1913-1920. DOI: 10.1136/ijgc-2023-004825. View

11.

Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M . Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26):2495-2505. DOI: 10.1056/NEJMoa1810858. View

12.

Piedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S . Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecol Oncol. 2023; 167(3):417-422. DOI: 10.1016/j.ygyno.2022.10.014. View

13.

Feng Z, Shao D, Cai Y, Bi R, Ju X, Chen D . Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. J Ovarian Res. 2023; 16(1):53. PMC: 10015784. DOI: 10.1186/s13048-023-01129-x. View

14.

Gonzalez-Martin A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M . Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25):2391-2402. DOI: 10.1056/NEJMoa1910962. View

15.

Rawert F, Luengas-Wurzinger V, Classen-Grafin von Spee S, Baransi S, Schuler E, Carrizo K . The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer. Arch Gynecol Obstet. 2022; 306(5):1665-1672. PMC: 9519707. DOI: 10.1007/s00404-022-06527-y. View

16.

You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson R . The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. Cancer Treat Rev. 2021; 100:102294. DOI: 10.1016/j.ctrv.2021.102294. View

17.

Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

18.

You B, Robelin P, Tod M, Louvet C, Lotz J, Abadie-Lacourtoisie S . CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clin Cancer Res. 2020; 26(17):4625-4632. DOI: 10.1158/1078-0432.CCR-20-0054. View

19.

You B, Colomban O, Heywood M, Lee C, Davy M, Reed N . The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. 2013; 130(2):289-94. DOI: 10.1016/j.ygyno.2013.05.013. View

20.

Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard A . Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clin Cancer Res. 2019; 25(17):5342-5350. DOI: 10.1158/1078-0432.CCR-18-3335. View